logo
FDA Elevates Recall of 64,800 Lbs. of Butter to Second-Highest Warning Level

FDA Elevates Recall of 64,800 Lbs. of Butter to Second-Highest Warning Level

Yahoo2 days ago
Bunge North America Inc. initially issued a voluntary recall of 64,800 lbs. of its European Style Butter Blend on July 14NEED TO KNOW
Bunge North America Inc. issued a nationwide recall of 64,800 lbs. (or 1,800 cases) of its European Style Butter Blend 1 lb. product on July 14 due to undeclared milk, which was not listed on the label
The Food and Drug Administration (FDA) raised the risk classification for the recall to Class II — the second-highest warning level — on July 30
The FDA said users who begins to experience any allergy symptoms by eating the affected product should 'stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine) and seek medical attention'A recent nationwide butter recall has been escalated by the U.S. Food and Drug Administration (FDA) to a higher risk level.The FDA raised the risk classification for the recall of one of Bunge North America Inc.'s butter products to Class II — the second-highest warning level — on Wednesday, July 30.
A Class II recall indicates 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA's website.
Bunge, which is based in Chesterfield, Mo., initially announced a voluntary recall of 64,800 lbs. (or 1,800 cases) of its European Style Butter Blend 1 lb. product on July 14 due to undeclared milk, which was not listed on the product label.
https://people-app.onelink.me/HNIa/kz7l4cuf
The company said the butter was 'packed in white paperboard cases,' with '36 blocks to a case,' and sent to a dozen distribution centers throughout the U.S. and one distribution center in the Dominican Republic. The lot code number for the butter is 5064036503.
The FDA did not say whether anyone has been affected in connection with the recall.
Bunge North America Inc. did not immediately respond to PEOPLE's request for comment on Aug. 2.
Milk is listed as one of the nine major food allergens on the FDA's website. The FDA said food-related allergic reactions can vary in severity and include mild symptoms, such as hives, face and lip swelling, vomiting, coughing or swelling.
However, people may also get more severe reactions like anaphylaxis, which 'causes the immune system to release a flood of chemicals' that can cause a person to go into shock and can be fatal, per the Mayo Clinic.
The FDA said that because of this, it 'enforces regulations' to require companies to list ingredients on packaged foods and beverages. The agency added that there are 'more specific labeling requirements' for foods that can 'cause allergies or other hypersensitivity reactions.'
The FDA advised that if anyone who eats the affected products begins to experience any allergy symptoms, they should 'stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine) and seek medical attention.'
Other major food allergens listed by the FDA include eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame.
Read the original article on People
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I'm almost 50, but I look 10 years younger. My secret weapon? This anti-aging eye cream that's on sale for $19
I'm almost 50, but I look 10 years younger. My secret weapon? This anti-aging eye cream that's on sale for $19

Yahoo

time39 minutes ago

  • Yahoo

I'm almost 50, but I look 10 years younger. My secret weapon? This anti-aging eye cream that's on sale for $19

Shoppers say it "reduced hyperpigmentation" and works "way better than expensive eye creams." When I turned 40, with a baby on the way, it became much more challenging to conceal the puffy eyes and dark circles of a sleepless night. A few years later, I added another kiddo, and tired eyes became my trademark look. I tried dozens of products to revive the delicate under-eye area, but it wasn't until CeraVe's Eye Repair Cream that I actually started to notice long-term improvements. As someone with easily irritated eyes, this lightweight cream is my daily go-to. So, when my four-year-old is up at 3 a.m. with an ear infection, CeraVe's eye cream will help to hide the evidence of a sleepless night. I'm not the only one who loves this affordable beauty product — according to our data, hundreds of Yahoo readers have also snapped it up. Read on to find out why I'm obsessed — and to shop it on sale for $19. The details This fragrance-free, ophthalmologist-tested eye cream contains three essential ceramides and hydrating hyaluronic acid. It's made with a patented delivery system that continually releases the ingredients so your eyes stay moisturized all day long. With continued regular use, you will notice a reduction in dark circles and under-eye puffiness. Apply a few dots of the cream to your under-eye area in the morning and evening, and gently smooth until fully absorbed. It works great alone or under makeup. The CeraVe eye cream, developed with dermatologists, is non-comedogenic and great for all skin types. What I like about it It's great for sensitive eyes: I love how the CeraVe cream moisturizes without irritating my sensitive eyes. It absorbs quickly and is a great primer for my under-eye concealer. Each application requires just a few dots of the product, so the little tube goes a long way. Dermatologist-approved: I also appreciate that the product has been recognized by the Canadian Dermatology Association and has been well-tested by experts. It's not just some gimmicky eye cream but one that has a lot of science behind it, which matters to me. Great for hyperpigmentation: With more than 3,600 reviews and a 4.3-star rating, it's clear I am not the only one who swears by this hydrating cream. One shopper said they wished they had found it sooner as it significantly "reduced hyperpigmentation" under their eyes. They stated that their under-eye area became 30 per cent lighter, which they say is a "big win." Not greasy: Another reviewer mentions how "non-greasy" the cream is and that it doesn't irritate sensitive eyes, while another person calls it a "wonderful product." $19 $24 at Amazon Other mature beauty & fashion recommendations: I'm a 48-year-old mom who loves shopping at Amazon — 12 summer tops I'm buying, all under $50 I tried on 13 Reitmans dresses on sale for under $75 — if you're in your 40s or 50s, these styles are seriously good These viral Amazon eye masks help make my bags look 'less puffy' — and they're on sale right now Room for improvement It's not a quick-fix eye cream: This product is great, but it's not a fast-acting wonder cream. You need to use it for several weeks, if not months, to see any remarkable improvements. Also, you can't skip applications, or it will set your results back. Commit to using it for a solid six months before you assess if it's working for you. Some Amazon reviewers mentioned they saw no visible difference after a few weeks; however, from personal experience, the cream takes time to do its thing. I promise, if you stick with it, your under-eye area will improve — just don't give up! It's not as hydrating as other eye creams: The eye cream could be a tad thicker; however, it probably wouldn't absorb as well if it was. CeraVe has a unique formula that may take a while to work, but once it does, it's great. My advice? Don't throw in the towel just yet. What reviewers are saying With hundreds of five-star reviews, I am far from the only fan of CeraVe's Eye Repair Cream. One reviewer, who has struggled with "hollow eyes" and "hyperpigmentation" their "whole life," says the eye cream has made their under-eye area "about 30 per cent lighter" — a "big win" for them. They write that their dark eye bags are "barely noticeable" after applying makeup. "I will definitely be buying [it] again." Another shopper agrees it's a "great cream for dark circles," adding that it works "way better than expensive eye creams." "Every dollar spent on it is worth it," they write. "My advice," echoes a third shopper: "Throw out all your expensive skin care" and only buy CeraVe products. They're "reasonably priced," and, importantly, "they work." Despite thousands of five-star reviews, some warn it's "not a miracle product" and agree it can take a few months to show noticeable results. The verdict I love CeraVe products, and this one is no exception. It's gentle on my eye area, and after using it for a few months straight, I saw significant improvements in my dark circles and under-eye puffiness. That said, if you are looking for something to quickly erase a night out with the girls or a long overseas flight, this is probably not going to provide the quick fix you need. This lightweight cream will yield results, but it's going to take some time. If you commit to using it twice a day for the next six months, I'm certain you will be impressed with what you see (and don't see) under your eyes in the morning.

Oscar Health (OSCR) Q2 Earnings: What To Expect
Oscar Health (OSCR) Q2 Earnings: What To Expect

Yahoo

timean hour ago

  • Yahoo

Oscar Health (OSCR) Q2 Earnings: What To Expect

Health insurance company Oscar Health (NYSE:OSCR) will be reporting earnings this Wednesday morning. Here's what to expect. Oscar Health beat analysts' revenue expectations by 6.9% last quarter, reporting revenues of $3.05 billion, up 42.1% year on year. It was a stunning quarter for the company, with a solid beat of analysts' EPS estimates. Is Oscar Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Oscar Health's revenue to grow 33.7% year on year to $2.97 billion, slowing from the 46% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.84 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Oscar Health has missed Wall Street's revenue estimates four times over the last two years. Looking at Oscar Health's peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts' expectations by 5.1%, and Alignment Healthcare reported revenues up 49%, topping estimates by 5.7%. CVS Health's stock price was unchanged after the resultswhile Alignment Healthcare was up 5.7%. Read our full analysis of CVS Health's results here and Alignment Healthcare's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Oscar Health is down 17% during the same time and is heading into earnings with an average analyst price target of $11.29 (compared to the current share price of $13.95). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect
GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect

Yahoo

timean hour ago

  • Yahoo

GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect

Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Wednesday after the bell. Here's what to expect. GoodRx met analysts' revenue expectations last quarter, reporting revenues of $203 million, up 2.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and a significant miss of analysts' customer base estimates. It lost -200,000 customers and ended up with a total of 6.4 million. Is GoodRx a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting GoodRx's revenue to grow 2.5% year on year to $205.7 million, slowing from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GoodRx has missed Wall Street's revenue estimates twice over the last two years. Looking at GoodRx's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts' expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell's stock price was unchanged following the results. Read our full analysis of Hims & Hers Health's results here and Omnicell's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. GoodRx is down 4.6% during the same time and is heading into earnings with an average analyst price target of $6.32 (compared to the current share price of $4.52). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store